CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- 4 Open-market sale Chief Executive Officer sold 6,400 shares at an average $39.60 ($253,425)
- 4 Open-market sale Director sold 2,500 shares at an average $44.78 ($111,944)
- 4 Grant or award Director acquired 1,500 shares (grant or award)
- 4 Grant or award Director acquired 1,500 shares (grant or award)
- 4 Grant or award Director acquired 1,500 shares (grant or award)
- 4 Grant or award Director acquired 1,500 shares (grant or award)
- 4 Grant or award Director acquired 1,500 shares (grant or award)
- 4 Grant or award Director acquired 1,500 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 45,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Executive Officer sold 8,800 shares at an average $48.56 ($427,288)
- 4 Open-market sale Chief Executive Officer sold 8,800 shares at an average $51.74 ($455,313)
- 4 Open-market sale EVP & Chief R & QA Officer sold 25,860 shares at $50.03 ($1,293,776)
- 4 Open-market sale SVP, Head of Global Commercial sold 16,334 shares at $45.02 ($735,357)
- 4 Open-market sale Director sold 12,286 shares at $43.57 ($535,301)
- 4 Shares withheld for taxes EVP & Chief Strategy Officer gave up 382 shares (to pay taxes)
- 4 Open-market sale EVP & Chief R & QA Officer sold 4,647 shares at an average $46.06 ($214,026)
- 4 Open-market sale Director sold 273 shares at $46.06 ($12,574)
- 4 Open-market sale EVP, R&D & Chief Scientific Of sold 25,775 shares at an average $45.30 ($1,167,480)
- 4 Open-market sale Chief Executive Officer sold 8,800 shares at an average $39.85 ($350,637)
Page 17 of 33 · 645 filings